Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Funded Surplus by Year
Net Funded Surplus ($M)
Novartis Net Funded Surplus: $2,650M in FY2025, up 142.5% from a year earlier.
Latest, FY2025
2,650
Period ended Dec 31, 2025
Change on a year earlier
+142.5%
1,093 in FY2024
History
3 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Note 25.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Funded Surplus ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,650 | +142.5% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 1,093 | +21.9% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 897 | – | Novartis Form 20-F (0001370368-25-000004) ↗ |
Cite this data
StockData. (2026). Novartis Net Funded Surplus ($M), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/pension-net-surplus
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.